



Intercell enters into strategic partnership with Wyeth for the use of its IC31™ adjuvant in various selected infectious disease vaccines

- » Worldwide agreement with Wyeth for the use of Intercell's fully synthetic novel adjuvant IC31™ in various selected infectious disease vaccine programs
- » Up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales
- » Further use of Intercell's adjuvant IC31™ in the development of novel vaccines with high unaddressed medical need.

September 12, 2006 (Vienna, Austria) – Intercell AG (VSE, "ICLL") today announced that it has closed a worldwide non-exclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31™ in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales.

"After having partnered a number of our vaccine candidates derived from our extremely successful Antigen Identification Program® with leading players in the vaccine industry, we are convinced that our adjuvant IC31™ will also generate significant value in the vaccine sector", says Alexander von Gabain, Intercell's Chief Scientific Officer. "We are happy that we could add Wyeth, a company with a high commitment to developing and commercializing innovative products in the vaccine sector, to the list of our top partners."

About IC31™

Vaccines, based on antigens alone, are not sufficient to provide full protection. Adjuvants are needed to educate the immune system to recognize and eliminate the pathogens efficiently.

IC31™ is an adjuvant that induces T-cell and B-cell responses by using a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.

Intercell currently uses IC31™ in collaborations with a number of global vaccine companies and biotech companies. These collaborations include amongst others the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its





proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.